Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as President of the Clinical TMS…
The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV ketamine formulation. The filing follows…
The world’s first distributed psychedelic conference debuts with a global hybrid experience, 100+ speakers, 60+ local gatherings [San Francisco] — Global…
FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision enables re-filing of an Abbreviated…
The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually.…
NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from ketamine products. The preservative has…
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be…
The new FDA voucher program aims to speed approval of drugs aligned with national health priorities. NRX-100, a preservative-free ketamine,…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is facing a severe ketamine shortage,…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and…